[1] Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA 2017;317:165–82. https://doi.org/10.1001/jama.2016.19043.
[2] Mokdad AH, Forouzanfar MH, Daoud F, Mokdad AA, El Bcheraoui C, Moradi-Lakeh M, et al. Global burden of diseases, injuries, and risk factors for young people’s health during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2016;387:2383–401. https://doi.org/10.1016/S0140-6736(16)00648-6.
[3] WHO | Raised blood pressure. WHO n.d. https://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/ (accessed March 26, 2020).
[4] Perkovic Vlado, Huxley Rachel, Wu Yangfeng, Prabhakaran Dorairaj, MacMahon Stephen. The Burden of Blood Pressure-Related Disease. Hypertension 2007;50:991–7. https://doi.org/10.1161/HYPERTENSIONAHA.107.095497.
[5] Reddy K. Srinath, Yusuf Salim. Emerging Epidemic of Cardiovascular Disease in Developing Countries. Circulation 1998;97:596–601. https://doi.org/10.1161/01.CIR.97.6.596.
[6] Addo J, Smeeth L, Leon DA. Hypertension in sub-saharan Africa: a systematic review. Hypertension 2007;50:1012–8. https://doi.org/10.1161/HYPERTENSIONAHA.107.093336.
[7] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet 2005;365:217–23. https://doi.org/10.1016/S0140-6736(05)17741-1.
[8] Opie Lionel H., Seedat Yackoob K. Hypertension in Sub-Saharan African Populations. Circulation 2005;112:3562–8. https://doi.org/10.1161/CIRCULATIONAHA.105.539569.
[9] Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-saharan Africa: a systematic review and meta-analysis. Hypertension 2015;65:291–8. https://doi.org/10.1161/HYPERTENSIONAHA.114.04394.
[10] Flack John M., Sica Domenic A., Bakris George, Brown Angela L., Ferdinand Keith C., Grimm Richard H., et al. Management of High Blood Pressure in Blacks. Hypertension 2010;56:780–800. https://doi.org/10.1161/HYPERTENSIONAHA.110.152892.
[11] Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H, et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet 2009;5:e1000564. https://doi.org/10.1371/journal.pgen.1000564.
[12] Young JH, Chang Y-PC, Kim JD-O, Chretien J-P, Klag MJ, Levine MA, et al. Differential Susceptibility to Hypertension Is Due to Selection during the Out-of-Africa Expansion. PLOS Genetics 2005;1:e82. https://doi.org/10.1371/journal.pgen.0010082.
[13] Tiffin N, Meintjes A, Ramesar R, Bajic VB, Rayner B. Computational Analysis of Candidate Disease Genes and Variants for Salt-Sensitive Hypertension in Indigenous Southern Africans. PLOS ONE 2010;5:e12989. https://doi.org/10.1371/journal.pone.0012989.
[14] Falkner B, Kushner H. Effect of chronic sodium loading on cardiovascular response in young blacks and whites. Hypertension 1990;15:36–43.
[15] Howard G, Lackland DT, Kleindorfer DO, Kissela BM, Moy CS, Judd SE, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med 2013;173:46–51. https://doi.org/10.1001/2013.jamainternmed.857.
[16] Geldsetzer P, Manne-Goehler J, Marcus M-E, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet 2019;394:652–62. https://doi.org/10.1016/S0140-6736(19)30955-9.
[17] Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 2017;389:1035–42. https://doi.org/10.1016/S0140-6736(17)30260-X.
[18] Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. The American Journal of Medicine 2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038.
[19] Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The Journal of Clinical Hypertension 2002;4:393–404. https://doi.org/10.1111/j.1524-6175.2002.02045.x.
[20] Whelton Paul K., Carey Robert M., Aronow Wilbert S., Casey Donald E., Collins Karen J., Dennison Himmelfarb Cheryl, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269–324. https://doi.org/10.1161/HYP.0000000000000066.
[21] Organization WH. Prevention of cardiovascular disease : guidelines for assessment and management of total cardiovascular risk. World Health Organization; 2007.
[22] Organization WH, Group IS of HW. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 2003;21:1983–1992.
[23] Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines n.d.:24.
[24] Seedat YK. Trial of atenolol and chlorthalidone for hypertension in black South Africans. Br Med J 1980;281:1241–3.
[25] Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Hond ED, et al. Efficacy of Different Drug Classes Used to Initiate Antihypertensive Treatment in Black Subjects: Results of a Randomized Trial in Johannesburg, South Africa. Arch Intern Med 2001;161:965–71. https://doi.org/10.1001/archinte.161.7.965.
[26] M’Buyamba-Kabangu JR, Anisiuba BC, Ndiaye MB, Lemogoum D, Jacobs L, Ijoma CK, et al. Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa. J Hum Hypertens 2013;27:729–35. https://doi.org/10.1038/jhh.2013.56.
[27] Odili AN, Ezeala-Adikaibe B, Ndiaye MB, Anisiuba BC, Kamdem MM, Ijoma CK, et al. Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients. Trials 2012;13:59. https://doi.org/10.1186/1745-6215-13-59.
[28] Djoumessi RN, Noubiap JJN, Kaze FF, Essouma M, Menanga AP, Kengne AP, et al. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. BMC Research Notes 2016;9:187. https://doi.org/10.1186/s13104-016-1987-5.
[29] Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. New England Journal of Medicine 2019;380:2429–39. https://doi.org/10.1056/NEJMoa1901113.
[30] Mary D. TANZANIA STEPS SURVEY REPORT 2012 n.d.:154.
[31] Vanobberghen F, Letang E, Gamell A, Mnzava DK, Faini D, Luwanda LB, et al. A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS ONE 2017;12:e0180983. https://doi.org/10.1371/journal.pone.0180983.
[32] Letang E, Kalinjuma AV, Glass TR, Gamell A, Mapesi H, Sikalengo GR, et al. Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. Swiss Med Wkly 2017;147:w14485. https://doi.org/10.4414/smw.2017.14485.
[33] Rodríguez-Arbolí E, Mwamelo K, Kalinjuma AV, Furrer H, Hatz C, Tanner M, et al. Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. PLoS ONE 2017;12:e0172089. https://doi.org/10.1371/journal.pone.0172089.
[34] Albrecht S, Franzeck FC, Mapesi H, Hatz C, Kalinjuma AV, Glass TR, et al. Age-related comorbidities and mortality in people living with HIV in rural Tanzania: data from a prospective cohort study. AIDS 2019. https://doi.org/10.1097/QAD.0000000000002171.
[35] Mchomvu E, Mbunda G, Simon N, Kitila F, Temba Y, Msumba I, et al. Diagnoses made in an Emergency Department in rural sub-Saharan Africa. Swiss Med Wkly 2019;149:w20018. https://doi.org/10.4414/smw.2019.20018.
[36] Lesotho_2012_STEPS_fact_sheet.pdf n.d.
[37] Labhardt ND, Müller UF, Ringera I, Ehmer J, Motlatsi MM, Pfeiffer K, et al. Metabolic syndrome in patients on first-line antiretroviral therapy containing zidovudine or tenofovir in rural Lesotho, Southern Africa. Trop Med Int Health 2017;22:725–33. https://doi.org/10.1111/tmi.12872.
[38] Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–92. https://doi.org/10.1097/00004872-200311000-00002.
[39] Khetsi MT. STANDING EXPERT COMMITTEE n.d.:254.
[40] WHO | WHO Model Lists of Essential Medicines. WHO n.d. http://www.who.int/medicines/publications/essentialmedicines/en/ (accessed July 14, 2020).
[41] Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339.
[42] Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918–29. https://doi.org/10.1056/NEJMoa0910975.
[43] Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, et al. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J 2019;40:2006–17. https://doi.org/10.1093/eurheartj/ehz300.
[44] Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059–68. https://doi.org/10.1016/S0140-6736(15)00257-3.
[45] Belghazi J, El Feghali RN, Moussalem T, Rejdych M, Asmar RG. Validation of four automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension. Vasc Health Risk Manag 2007;3:389–400.
[46] Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010;11:32. https://doi.org/10.1186/1745-6215-11-32.
[47] Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA 2019;321:1610–20. https://doi.org/10.1001/jama.2019.3087.
[48] Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594–604. https://doi.org/10.1001/jama.2012.87802.
[49] Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917–30. https://doi.org/10.1002/sim.1296.
[50] Norton EC, Miller MM, Kleinman LC. Computing Adjusted Risk Ratios and Risk Differences in Stata. The Stata Journal 2013;13:492–509. https://doi.org/10.1177/1536867X1301300304.
[51] Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 2012;345:e5840. https://doi.org/10.1136/bmj.e5840.
[52] Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001;52:223–8. https://doi.org/10.1046/j.0306-5251.2001.01397-3.x.
[53] O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731–68. https://doi.org/10.1097/HJH.0b013e328363e964.
[54] Myers MG, Valdivieso M, Chessman M, Kiss A. Can sphygmomanometers designed for self-measurement of blood pressure in the home be used in office practice? Blood Press Monit 2010;15:300–4. https://doi.org/10.1097/MBP.0b013e328340d128.
[55] SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939.
[56] Kjeldsen SE, Mancia G. The Un-Observed Automated Office Blood Pressure Measurement Technique Used in the SPRINT Study Points to a Standard Target Office Systolic Blood Pressure <140 mmHg. Curr Hypertens Rep 2017;19:3. https://doi.org/10.1007/s11906-017-0700-y.
[57] Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 2016;316:1093–103. https://doi.org/10.1001/jama.2016.12195.
[58] Edejer TT-T, World Health Organization, editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
[59] Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 2015;3:e712-723. https://doi.org/10.1016/S2214-109X(15)00069-8.
[60] WHO | Noncommunicable diseases country profiles 2018. WHO n.d. http://www.who.int/nmh/countries/en/ (accessed March 26, 2020).
[61] Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. The Lancet 2007;370:1929–38. https://doi.org/10.1016/S0140-6736(07)61696-1.
[62] Amuyunzu-Nyamongo M. Need for a multi-factorial, multi-sectorial and multi-disciplinary approach to NCD prevention and control in Africa. Glob Health Promot 2010;17:31–2. https://doi.org/10.1177/1757975910363928.
[63] Mapesi H, Paris DH. Non-Communicable Diseases on the Rise in Sub-Saharan Africa, the Underappreciated Threat of a Dual Disease Burden. Praxis 2019; 108:997–1005. https://doi.org/10.1024/1661-8157/a003354.
[64] Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007;44:1625–31. https://doi.org/10.1086/518285.
[65] McDonald CL, Kaltman JR. Cardiovascular disease in adult and pediatric HIV/AIDS. J Am Coll Cardiol 2009;54:1185–8. https://doi.org/10.1016/j.jacc.2009.05.055.
[66] Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13:453–68. https://doi.org/10.1111/j.1468-1293.2012.00996.x.
[67] Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537–48. https://doi.org/10.1097/QAD.0b013e32833a0918.
[68] UNAIDS data 2019 | UNAIDS n.d. https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data (accessed February 20, 2020).
[69] Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015;162:192–204. https://doi.org/10.7326/M14-1539.
[70] Zeller A, Sigle J-P, Battegay E, Martina B. Value of a standard urinary dipstick test for detecting microalbuminuria in patients with newly diagnosed hypertension. Swiss Med Wkly 2005;135:57–61. https://doi.org/2005/03/smw-10859.
[71] Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. 1949. Ann Noninvasive Electrocardiol 2001;6:343–68. https://doi.org/10.1111/j.1542-474x.2001.tb00129.x.
[72] Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2010;159:652–8. https://doi.org/10.1016/j.ahj.2009.12.035.
[73] Nascimento BR, Beaton AZ, Nunes MCP, Tompsett AR, Oliveira KKB, Diamantino AC, et al. Integration of echocardiographic screening by non-physicians with remote reading in primary care. Heart 2019;105:283–90. https://doi.org/10.1136/heartjnl-2018-313593.
[74] Cuspidi C, Rescaldani M, Sala C. Prevalence of echocardiographic left-atrial enlargement in hypertension: a systematic review of recent clinical studies. Am J Hypertens 2013;26:456–64. https://doi.org/10.1093/ajh/hpt001.
[75] Su G, Cao H, Xu S, Lu Y, Shuai X, Sun Y, et al. Left atrial enlargement in the early stage of hypertensive heart disease: a common but ignored condition. J Clin Hypertens (Greenwich) 2014;16:192–7. https://doi.org/10.1111/jch.12282.
[76] Maamari RN, Keenan JD, Fletcher DA, Margolis TP. A mobile phone-based retinal camera for portable wide field imaging. Br J Ophthalmol 2014;98:438–41. https://doi.org/10.1136/bjophthalmol-2013-303797.
[77] Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417–28. https://doi.org/10.1056/NEJMoa0806182.
[78] Iyalomhe GBS, Omogbai EKI, Isah AO, Iyalomhe OOB, Dada FL, Iyalomhe SI. Efficacy of initiating therapy with amlodipine and hydrochlorothiazide or their combination in hypertensive Nigerians. Clin Exp Hypertens 2013;35:620–7. https://doi.org/10.3109/10641963.2013.776570.